Skip to main content

Table 3 Medication (n = 780)

From: Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants

  Group A
Briding
(n = 111)
Group B
VKA
(n = 318)
Group C
DOAC
(n = 351)
p-value
A-B
p-value
A-C
p-value
B-C
Beta-blockers (n, %) 106 (95.5) 277 (87.1) 304 (86.6) 1.0 0.009 0.012
ACE-inhibitors (n, %) 57 (51.4) 144 (45.3) 83 (23.6) < 0.001 < 0.001 0.272
AT1 antagonists (n, %) 26 (23.4) 69 (21.7) 90 (25.6) 0.238 0.707 0.693
Diuretics (n, %) 28 (25.2) 112 (35.2) 104 (29.6) 0.136 0.401 0.060
Aspirin (n, %) 13 (11.7) 21 (6.6) 9 (2.6) 0.014 < 0.001 0.102
Anti-platelet drugs (n, %) 3 (2.7) 11 (3.5) 1 (0.3) 0.002 0.045 1.0
Statins (n, %) 40 (36.0) 103 (32.4) 88 (25.1) 0.04 0.029 0.485
  1. Legend: ACE angiotensin-converting enzyme, AT1 angiotensin II type 1, Bridging interrupted vitamin-K-antagonist, DOAC uninterrupted non-vitamin-K-anticoagulants